Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Details
Category: Globe NewsWire News Distribution Service

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an upsized underwritten public offering of 10,000,000 shares of its common stock at a price to the…


Posted: 2024-10-09 03:55:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | crinetics | pharmaceuticals | announces


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - Newscast

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jan 2025 14:54:00 GMT Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Fri, 10 Jan 2025 04:00:00 GMT NDAQ:CRNX) Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) ...

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Fri, 10 Jan 2025 04:00:00 GMT SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals ... obesity and GPCR-targeted oncology indications. This press release contains forward-looking statements within the ...

Crinetics announces results from Phase 2 trial of atumelnant

Thu, 09 Jan 2025 22:25:00 GMT Crinetics (CRNX) Pharmaceuticals announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia, CAH, study of investigational atumelnant, a novel, once-daily oral ...

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Thu, 02 Jan 2025 02:53:00 GMT Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for ...


Blow Us A Whistle